The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro

Elke Tatjana Aristizabal Prada,Svenja Nölting,Gerald Spoettl,Julian Maurer,Christoph J. Auernhammer

The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro

2018

Elke Tatjana Aristizabal Prada
Svenja Nölting
Gerald Spoettl
Julian Maurer
Christoph J. Auernhammer

Background/Aim: Cyclin-dependent kinases (CDKs) are crucial for cell cycle regulation, and alterations in the cell cycle are often observed in human cancer. CDK4/

Keywords:

Endocrinology
Cancer
Ribociclib
Cell cycle
Internal medicine
Cyclin-dependent kinase 4
In vitro
Neuroendocrine tumors
Cyclin-dependent kinase
Cell biology
Biology
Kinase
dual targeting

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations